Institut du Cancer de Montpellier - Val d'Aurelle: Colorectal Neoplasms trials
The registry lists 13 Colorectal Neoplasms studies with Institut du Cancer de Montpellier - Val d'Aurelle as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 2Phase 2 5Phase 3 2No phase 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer PatientsActive, not recruitingNCT03829462Phase 3Results posted
- Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal CancerCompletedNCT03828799Phase 1/2Results posted
- Feasibility of 2 Interventions to Reduce Fatigue in Patients With Chemotherapy for Metastatic Colorectal CancerTerminatedNCT04999306Not applicable
- Clinical Database of Colorectal Robotic SurgeryActive, not recruitingNCT04013152
- Circulating-free DNA Assessment as a Tool to Predict Colorectal Cancer in Subjects With a Positive Fecal Immunoassay.CompletedNCT03981679Not applicable
- Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal CancerCompletedNCT03914170
- Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With mCRC (Metastatic Colorectal Cancer) During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) TherapyActive, not recruitingNCT03908788Not applicable
- Comparison of KRAS/BRAF Mutational Status With Conventional Techniques and Plasma Samples AnalysisCompletedNCT02784639Not applicable
- 2nd-line Treatment of Metastatic Colorectal CancerTerminatedNCT01532804Phase 2
- Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS MutationCompletedNCT00989469Phase 1/2
- Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal CancerCompletedNCT00628368Not applicable
- Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal CancerCompletedNCT00556413Phase 2
- Intensified Chemotherapy in CRC After Resection of Liver MetastasesCompletedNCT00208260Phase 2/3